AML	Acute Myeloid Leukemia
ALL	Acute Lymphoblastic Leukemia
CML	Chronic Myeloid Leukemia
MM	Multiple Myeloma
B-ALL	B-cell Acute Lymphoblastic Leukemia
T-ALL	T-cell Acute Lymphoblastic Leukemia
BCR-ABL	Breakpoint Cluster Region-Abelson
FLT3-ITD	FMS-like Tyrosine Kinase 3 Internal Tandem Duplication
DNMT3A	DNA Methyltransferase 3 Alpha
NPM1	Nucleophosmin 1
WT1	Wilms Tumor 1
ASXL1	Additional Sex Combs Like 1
SRSF2	Serine/Arginine-Rich Splicing Factor 2
U2AF1	U2 Small Nuclear RNA Auxiliary Factor 1
RUNX1	Runt Related Transcription Factor 1
IGH	Immunoglobulin Heavy Chain
del(13q)	Deletion of chromosome 13q
+1q	Addition of chromosome 1q
SNPs	Single Nucleotide Polymorphisms
TKI	Tyrosine Kinase Inhibitor
CNS	Central Nervous System
WBC	White Blood Cell
FISH	Fluorescence In Situ Hybridization
NIH	National Institutes of Health
PTSD	Post-Traumatic Stress Disorder
BSA	Body Surface Area
ESMO	European Society for Medical Oncology
COG	Children’s Oncology Group
AMLCG	AML Cooperative Group
SLA	Service Level Agreement
DNA	Deoxyribonucleic Acid
RNA	Ribonucleic Acid
OS	Overall Survival
PFS	Progression-Free Survival
MMR	Major Molecular Response
CCyR	Complete Cytogenetic Response
SEER	Surveillance, Epidemiology, and End Results
MMRF	Multiple Myeloma Research Foundation
ASCT	Autologous Stem Cell Transplantation
EBMT	European Group for Blood and Marrow Transplantation
HDCT	High-Dose Chemotherapy
TreoMel	Treosulfan and Melphalan
AUC	Area Under the Curve
RRMM	Relapsed/Refractory Multiple Myeloma
EFS	Event-Free Survival
EAPC	Estimated Annual Percentage Change
LOY	Loss of Y Chromosome
HSPCs	Hematopoietic Stem and Progenitor Cells
A:N	Abnormal-to-Normal (ratio)
CI	Confidence Interval
HR	Hazard Ratio
REL	Relapse Rate